Pharma-Bio Serv (PBSV) FCF Margin (2010 - 2026)

Pharma-Bio Serv's FCF Margin history runs 16 years deep, the most recent figure standing at 13.6% for Q2 2026.

• FCF Margin for Q2 2026 came in at 13.6%, down 95.0% year-over-year; the trailing twelve-month figure through Apr 2026 was 2.7% (up 1271.0% YoY), and the FY2025 annual result was 2.46%, up 518.0% from the prior year.
• FCF Margin came in at 13.6% for Q2 2026 at Pharma-Bio Serv, up from 17.1% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 30.47% in Q1 2024 to a low of 29.47% in Q2 2024.
• A 5-year average of 0.48% and a median of 4.43% in 2023 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 4870 bps in 2024 and surged 3974 bps in 2025, its largest moves.
• Over 5 years, FCF Margin stood at 5.35% in 2022, then soared by 61 bps to 8.62% in 2023, then sank by 139 bps to 3.37% in 2024, then surged by 486 bps to 12.99% in 2025, then slumped by 205 bps to 13.6% in 2026.
• The last three FCF Margin figures came in at 13.6% (Q2 2026), 17.1% (Q1 2026), and 12.99% (Q4 2025), per Business Quant data.